CENOVAPHARMA

PARTNER OF CHOICE

CONTENT
About Cenovapharma

Our Capabilities
Our Products Cenovapharma Team Current Sales and Force Size & Structure Contact Us

ABOUT CENOVAPHARMA
Cenovapharma specializes in providing innovative and generic healthcare products to the Middle East, Africa, Turkey and the Caspian Regions. Cenovapharma's focused sales and marketing expertise coupled with in depth know-how provides biotechnology and pharmaceutical companies with a local partner to commercialize cutting-edge therapeutic products.

PARTNER OF CHOICE

Cenovapharma focuses on the licensing and commercialization of high-value products such as diabetes, cardiovascular, ophthalmic and oncologic productsdiseases with sharply rising regional incidence and prevalence.
Headquartered in Istanbul, Turkey, Cenovapharma was founded in 2010 by Faik Somer, an individual who has 22 years of experience in pharmaceutical industry . Another major partner of Cenovapharma is the Polish pharmaceutical company, Polpharma. With a history of 75 years, and offices in more than 15 major markets and 2600 employees, Polpharma brings global connections and expertise to Cenovapharma. Cenovapharma has established regulatory, finance, supply chain, medical affairs, business development and strong sales and marketing capabilities. This integrated strategy and regional focus makes Cenovapharma the "partner-of-choice" for US, European, and Asian biotech and pharmaceutical companies seeking access to the rapidly expanding markets of the Middle East, Africa, Turkey and Caspian Regions.

OUR CAPABILITIES
Istanbul-based management team with proven success and expertise in Middle East, Africa, Turkey and Caspian Market Healthcare

Strong commercilization know-how in selected therapeutic areas

supported by strong relations with key opinion leaders and all relevant stakeholders Fully aligned with good business practices and corporate governance

Global company approach with local know-how and speed

Strong financial structure Ease of access to key decision makers including government authorities, ministry of health, financial systems,social security system, insurance providers and manufacturers-distributors

CENOVAPHARMA PRODUCTS
Description & Indication Cardyn is an atorvastatin which treats hyperlipidemia.

Benefits Primary hypercholesterolemia Reduces total cholesterol in dyslipidemia patients Reduces LDL-cholesterol Reduces triglycerides Increase HDL-C levels

Regulatory Status Approved in Turkey.

License Partner TRIPHARMA

CENOVAPHARMA PRODUCTS
Description & Indication Diameprid is a glimeprid which treats Type 2 Diabetes
Benefits Controls blood glucose level

Regulatory Status Approved in Turkey.

License Partner MECOM

CENOVAPHARMA PRODUCTS
Description & Indication Glynose is an acarbose which treats Type 2 Diabetes. Benefits Reduces blood glucose level Regulatory Status Approved in Turkey. License Partner

CENOVAPHARMA PRODUCTS
GLOKOPROST (latanoprost ophthalmic) Solution 0.005% (50 g/mL)
Description & Indication GLOKOPROST Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Benefits Reduces intraocular pressure.

Regulatory Status Approved in Turkey.

License Partner

CENOVAPHARMA PRODUCTS
TDOMX (dorzolamid HCl - timolol maleat) Solution 2% dorzolamid HCl, 0.5% timolol maleat

Indication TDOMX is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma, ocular hypertension, pseudoexfoliative or other secondary open-angle glaucoma where combination therapy is appropriate. Benefits Reduces intraocular pressure. Regulatory Status Approved in Turkey.

License Partner

CENOVAPHARMA PRODUCTS
ACTOS
Description: Each tablet includes pioglitazone HCI equalivent to 15 mg pioglitazone. Indication : Actos is a pioglitazone which treats Type 2 diabetes mellitus Regulatory Status Approved in Turkey. License Partner

CENOVAPHARMA TEAM
Faik SOMER Founder, Chairman of the Board and Chief Executive Officer
Faik Somer founded Cenovapharma in 2010 shortly after leaving MSD. Mr. Somer began his management career in pharmaceutical industry over 22 years ago at FAKO, Pharmaceutical Leading Company in in-licensing and generics. He established Merck Sharp Dohme license-business from base zero to 15 million dollars in 3 years time. He managed the process of buying back the business from the licensee and established MSD as a full-fledge organization in the Turkish Market through launching full portfolio of the company. He developed the business as the managing director to 200 million dollars, a 500 people company in 9 years time. His proven success resulted in expanded responsibilities in the title of Vice President managing Central Eastern Europe, Central Asian Region grew the business from 300 million dollars to 700 milllion dollars in 5 years.

In his last role in MSD, Mr. Somer served as the President of Central Eastern Europe, Central Asia and Middle East, Africa Region; so-called the emerging markets managing more than 110 Countries. Again Mr. Somer rose to the task, growing the business from 700 million dollars to 2 billion dollars in 3 years time.

CENOVAPHARMA TEAM
Selim GRAY Co Founder ,Managing Partner
Selim Giray started his career as a sales representative in 1999. After 2 years of experience in sales, in 2001 he decided to continue his career in pharmaceutical industry with Roche as a brand manager for OTC products. Shortly after, Mr. Giray joined Merck Sharp Dohme in 2004 as a brand manager for CV products, and successfully launched Ezetimibe and Ezetimibe/Simvastatin, leading the products to become most successful launches in Europe. He then promoted to become Regional Marketing Manager for Vaccines for the Middle East and Eastern Europe Region in 2006. Mr. Giray, became a member of board in MSD Turkey in 2008, in charge of all ethical drug sales of the company. Mr. Giray was in charge of a 300 person staff and 200 million dollars sales. Beside his successful career in the pharmaceutical industry, he created and led the first industry-academia partnership program in Turkey- a 52 week Pharmaceutical Industry Brand Manager Certification Program in cooperation with Bilgi University.

Aslan ASLANAI Chief Financial Officer

Aslan Aslana began his career in banking sector as a management trainee in 1998 at Iktisat Bank. Shortly after, he joined MSD Finance Department. Mr. Aslana became a manager in MSD with the responsibilities of planning, treasury and pricing. Due to his proven success in finance and business orientation,he was appointed as a project realization officer undertaking sales and marketing. He played a key role in establishing new commercial model in MSD, based on changing needs of industry capatilizing opportunities to the benefit of the company. After the merge of SP and MSD he was again assigned to a key role as the leader of the integration team. In 2010, he joined Cenovapharma as CFO, establishing financial structure as well as other support departments. Mr. Aslana also holds six sigma green belt certificate.

CENOVAPHARMA TEAM
Zeynep YAZGAN AKIALP Human Resources Director
Zeynep Yazgan Akalp started her career in pharmaceutical industry in 1998 with Roche as a Brand Manager. In 2000, she joined MSD Turkey organization, responsible for ARB franchise, one of the highest contributing products in company portfolio at the time. She played a key role in the success of the ARB franchise's expansion through successful launches of new forms and key studies.ARBbecome the market leader during her leadership as the Senior Brand Manager forARBfranchise. She also led the Regional Marketing Team for CEE (Central Eastern Europe) contributing to the regional marketing strategies as well as ensuring successful launches in other countries in the region. In 2006, she decided to broaden her contribution to the company through undertaking a strategic role in HR. Her business background combined with strategic partnership understanding she embraced for HR, created a strong value and input for the company. In her role in HR, she focused on strategic areas such as - succession planning, strategic recruitment, performance management, and leadership. She has re-established the HR organization inline with Business Partner Model, positioning HR as strategic partner for the business. Through this revitalization of the department and understanding the needs of the business, she was able to successfully lead a major restructuring within the company supporting the management vision and goals. As the HR lead for the organization she was a board member as well as a member of the CEEMEA HR leadership team. Mrs. Akialp joined Cenovapharma in 2010 responsible for establishing the organization based on strategy, as well as establishing key HR processes.

SALES FORCE SIZE & STRUCTURE

Targeted Specialized fields for; - Cardiovasculer - Diabetes - Ophthalmology Coverage - 67 Cities in Turkey - 7 regions 10 Regional Managers & 100 Region Sales Representatives

CONTACT US
Corporate address:
Cenova Salk rnleri San. ve Tic. A. Eski Bykdere Asfalt No: 17-5 Gney Plaza Kat:4 34398 Maslak - STANBUL

Contact Person:
Faik SOMER, Founder, CEO Selim GRAY, Co Founder, Managing Partner

Office:
+90 (212) 285 04 04

Fax number:
+90 (212) 285 17 17

Email address: faik.somer@cenova.com selim.giray@cenova.com